Skip to main content
S&P 5007,592.40-0.58%DOW52,022.21-0.68%NASDAQ26,091.78-0.62%BTC$77,165.00-1.57%ETH$2,463.62-0.62%GOLD$4,372.10-1.99%OIL$102.07+6.27%
Smart Investors Daily
LM

NASDAQ · LMDX

LumiraDx Limited

Healthcare · Medical - Diagnostics & Research

$0.02

Up+$0.00 (+0.00%)

Updated Sep 10, 2026, 7:10 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.1M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
— – —
Volume
120.55M
Avg. volume
120.55M

Price performance

LMDX price history

1M range · 0 trading sessions · Daily adjusted prices

LMDX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest LMDX news

The latest Smart Investors Daily articles mentioning LMDX.

Stock researchCompany · Overview

LMDX research

Overview

Company profile and research snapshot.

Company profile

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
LMDX recent ratings
DateFirmRatingTarget
Aug 28, 2023Raymond JamesOutperform—
May 17, 2023Goldman SachsNeutral—
May 17, 2023Ladenburg ThalmannBuy—
May 17, 2023Raymond JamesOutperform—
Apr 10, 2023Raymond JamesOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jan 5, 2024

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards.

Benzinga · Jan 2, 2024

Dow Turns Higher; Anavex Life Sciences Shares Plunge

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&P 500 also fell, dropping, 0.45% to 4,748.51. Check This Out: How To Earn $500 A Month From Annaly Capital Management Stock   Leading and Lagging Sectors   Energy shares rose by 1.5% on Tuesday. In trading on Tuesday, information technology shares fell by 2.2%.   Top Headline   Rivian Automotive Inc (NASDAQ: RIVN) reported vehicle production and delivery totals for the fourth quarter. The company produced 17,541 vehicles (vs. 10,020) at its manufacturing facility in Normal, Illinois, and delivered 13,972 cars in the fourth quarter. The latest-quarter delivery was below the third-quarter figure of 15,564 and below analysts' estimate of 14,430, as per Reuters.   Equities Trading UP   Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) shares shot up 194% to $17.70 after the company announced topline data from the PACIFIC Study evaluating bexicaserin in patients with Developmental and Epileptic Encephalopathies. Shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) got a boost, surging 25% to $10.54 after the company announced a strategic collaboration and capsid license agreement ...

GlobeNewswire Inc. · Dec 29, 2023

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx’s innovative point of care technology to Roche.

PennyStocks · Nov 30, 2023

Best Penny Stocks Today? 3 To Watch Under $4 Now

Penny stocks under $4 to watch now. The post Best Penny Stocks Today? 3 To Watch Under $4 Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By